Based on the review, the researchers promote the integration of GLP-1 receptor agonists as a primary treatment for obesity in ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Glucagon-like peptide-1 receptor agonists are FDA-approved medications that mimic the action of a naturally occurring hormone ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related hospitalisations. Read more!

A long-term study suggests GLP-1 agonists, especially semaglutide ... potentially mediated by dopamine modulation in reward mechanisms. Furthermore, genetic associations between GLP-1 receptors ...

In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist resulted in higher week-72 rates of steatohepatitis resolution without worsening of liver fibrosis (63% vs 34% ...

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcohol effects, a new study suggests. Glucagon-like peptide-1 receptor (GLP-1) agonists — which contain either semaglutide or ...

It stands to reason, then, that if there are similar mechanisms that drive us to overeat and take drugs, and a GLP-1 agonist works on the one for overeating, then a GLP-1 agonist could also ...

which is the Company’s first generic injectable glucagon-like peptide-1 (GLP-1) agonist and reflects its innovation capabilities in peptide development and drug-device combinations. Resubmission ...

A new study says that type 2 diabetes medications GLP-1 agonists and SGLT2 inhibitors may help lower a stroke survivor’s risk of experiencing a subsequent stroke, heart attack, or death ...